<DOC>
	<DOCNO>NCT00916461</DOCNO>
	<brief_summary>The purpose study determine whether addition minocycline placebo treatment usual ( TAU ) : 1. prevents accumulation negative symptom intellectual decline follow first episode non-affective psychosis ; 2. whether minocycline stabilize efficacy antipsychotic .</brief_summary>
	<brief_title>Role Minocycline First Episode Psychosis</brief_title>
	<detailed_description>Background : There increase clinical , neuropsychological image evidence schizophrenia involve progressive process time first episode late life . However , clear system affect part brain . In two Stanley first episode cohort Manchester ( Stirling et al , 2004 , ) group elderly patient schizophrenia ( Gabrovska-Johnson et al 2004 ) , evidence deterioration visuo-spatial function find . This imply right-hemisphere pathology . Other evidence suggest initiation schizophrenia may involve left-sided pathology ( Lawrie et al 2002 ) could right hemisphere pathology may follow leave give rise deficit chronic schizophrenia ( Gabrovska-Johnson et al 2004 ) . If , early treatment neuroprotective agent might prevent accumulation deficit symptom cognitive impairment . Minocycline tetracycline antibiotic prove long-term high dose safety human , routinely use treat acne rheumatoid arthritis demonstrate act non-steroidal anti-inflammatory , well antimicrobial drug . Minocycline , unlike tetracycline , cross blood-brain barrier . This related compound show neuroprotective property rat model ischemic brain damage , glutamate neurotoxicity cell culture rat model Huntington 's disease slow progression ( Chen et al , 2000 ; Yrjanheikki et al , 1999 ) . Minocycline delay disease onset extend survival amyotrophic lateral sclerotic mouse ( Shan Zhu et al 2002 ) . Minocycline various property include inhibition capsases , inhibition microglial activation , reduce cyclooxygenase-2 expression reduce prostaglandin E ( 2 ) formation . Furthermore , inhibit formation inducible nitric oxide - mechanism glial activation . All mechanism implicate schizophrenia . All mechanism implicate schizophrenia . Because broad spectrum action , consider minocycline important candidate molecule prevention deterioration schizophrenia . Based evidence far propose randomise double blind placebo control study minocycline add treatment-as-usual ( TAU ) first-episode psychosis . Study Hypotheses : - A neurodegenerative process , initially mark leave hemisphere , late adolescence responsible onset schizophrenia risk . - Continuation process onset extension right hemisphere cause accumulation deficit symptom cognitive decline . - Glutamate antagonism may enhance antipsychotic effect dopamine receptor blockade prevent attenuation efficacy long-term treatment . TREATMENT : Minocycline widely available antibiotic give dos 50mg twice daily increase 200mgs per day . It use widely appear tolerate well . The study advisor , Dr. Serdar Dursun , use dos 200mg per day treatment Huntington 's disease ( Denovan-Wright et al 2002 ) . It widely available Pakistan Brazil give dose 50mg twice daily increase 100mg twice daily ( total 200mg per day ) ( British National Formulary : BNF maximum dose 200mg per day ) . As per counsel recommendation British National Formulary : `` minocycline medication swallow whole plenty fluid sit stand '' , allow effective absorption . Patients counsel 'the study medication swallow whole plenty fluid stand sit . ' Patients inform regard report side-effects cite BNF include ; nausea , vomit , diarrhoea , dysphagia , oesophageal irritation , anorexia , dizziness , tinnitus , vertigo , hypersensitivity reaction ( rash , exfoliative dermatitis , urticaria , angioedema , anaphylaxis , pericarditis ) , headache , visual disturbance , hepatotoxicity , pancreatitis , antibiotic associate colitis , blood dyscrasia , exacerbation systemic lupus erythematosus myasthenia gravis , rarely photosensitivity , skin , teeth , conjunctiva , tear sweat discoloration . NUMBER OF PATIENTS : Using data SOCRATES study , able calculate 40 patient per treatment arm detect group difference primary outcome measure , i.e , PANSS , give 85 % chance detect difference treatment group 4 point . The power estimate likely conservative three treatment group . The automated CSF measure detect 5 % group difference sample size . A minimum 52 complete patient necessary ( 26 complete patient per treatment group ) . Study Advisors : Prof Bill Deakin ( design ) , Prof Serdar Dursun ( scientific ) , Prof Shon Lewis ( clinical ) , Dr John Stirling ( cognition ) , Dr Paul Richardson ( cognition ) , Prof Graham Dunn ( analysis ) .</detailed_description>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Aged 18 65 year Diagnostic Statistical ManualIV ( DSMIV ) diagnose first episode psychosis , schizophrenia , schizoaffective disorder , psychosis otherwise specify schizophreniform disorder First episode ( within first 5 year diagnosis ) Competent willing give inform consent Medication remain stable 4 week prior baseline Able take oral medication likely complete require evaluation Female participant child bear capability must willing use adequate contraceptive duration study , , willing pregnancy test pretreatment ten weekly interval study medication Relevant medical illness [ renal , hepatic , cardiac , serious dermatological disorder exfoliative dermatitis , systemic lupus erythematosus ( SLE ) ] opinion investigator ( see section 6.2a ) Prior history intolerance tetracycline Concomitant penicillin therapy Concomitant anticoagulant therapy Presence seizure disorder , include clozapineinduced seizure Presently take valproic acid Any change psychotropic medication within previous six week Diagnosis substance abuse ( except nicotine caffeine ) dependence within last three month accord DSMIV criterion Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>First episode psychosis</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Minocycline</keyword>
	<keyword>neuroprotection</keyword>
	<keyword>First episode non affective psychosis</keyword>
	<keyword>With first five year illness</keyword>
</DOC>